​​​
  1. Jefferies retains ‘Buy’ on Natco, target price Rs 730

Jefferies retains ‘Buy’ on Natco, target price Rs 730

Natco reported a good set of results with revenues inline with expectation and margins 200bps ahead of expectation. Profit after tax came 6% ahead of expectation.

By: | Published: August 12, 2016 6:31 AM

Natco reported results better than expected led by strong Hep-C portfolio. Branded Hep-C sales were up 22% q-o-q. Key US launches timeline remains on track led by Tamiflu. We expect this to drive 55% EPS CAGR over FY16-19E. Additionally, it has a pipeline to grow at 20% CAGR post FY18. The stock is not impacted by any of the near term headwinds for the sector and we retain buy.

Natco reported a good set of results with revenues inline with expectation and margins 200bps ahead of expectation. Profit after tax came 6% ahead of expectation.

The key driver in the results was the strong growth in India business, especially Hep-C branded portfolio. Natco branded Hep-C sales stood at R1,310 million, up 22% q-o-q. Oncology business grew 17% y-o-y. Hep-C third party sales though were weaker at R136 million as competitors have started their own manufacturing. The company saw small R36 million sales from Hep-C in exports market.

We believe Natco is on the verge of a breakout in its US business with key launches in the next 12 months. We expect this to drive FY16-19E EPS CAGR of 55%. Its ‘known’ product pipeline would drive 20%+ earnings growth even post FY19E, in our view, a rarity in Indian pharma. We believe it is one of the best positioned Indian generic players to face sector headwinds. At 22.7x FY18E P/E, Natco is trading at a premium to the sector.

We believe that the premium could sustain given the better near-term growth and stronger medium-term product pipe-line. Retain buy and PT of R730.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top